January 2001
Worldwide Biotech;Jan2001, Vol. 13 Issue 1, p2
Trade Publication
Reports that the anti-cancer drug Virulizin from Lorus Therapeutics Inc. has demonstrated strong anti-tumor activity in mice containing human pancreatic tumor cells, which are resistant to gemcitabine.


Related Articles

  • AACR 2012.  // BioWorld Today;4/4/2012, Vol. 23 Issue 65, p8 

    The article reports that LOR-253 drug from Lorus Therapeutics Inc. combined with docetaxel resulted to significant and synergistic anticancer activity among patients with non-small-cell lung cancer (NSCLC) based on preclinical data.

  • Prostate Cancer News Headlines May 15, 2003--June 14, 2003.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p26 

    Presents an update on developments concerning prostate cancer treatment, compiled as of June 14, 2003. Lorus' plan to advance its anticancer drug, GTI-2501 into phase II clinical trial; Association of the drug, Zometa, with increased bone mineral density in prostate cancer treatment;...

  • FDA approves clinical trial protocol for Lorus' GTI-2040 in breast cancer.  // PharmaWatch: Cancer;September 2003, Vol. 2 Issue 9, p8 

    Reports that the United States Food and Drug Administration has approved an investigational new drug application filed by Lorus Therapeutics and the National Cancer Institute for a phase II clinical trial to investigate Lorus' lead antisense drug as a treatment for metastatic breast cancer in...

  • Lorus expands prostate cancer trial.  // PharmaWatch: Cancer;August 2004, Vol. 3 Issue 8, p11 

    Lorus Therapeutics Inc. has expanded its promising prostate cancer trial, a GTI-2501/docetaxel combination therapy being investigated in patients with asymptomatic or symptomatic hormone refractory prostate cancer, to two additional sites in Canada. The new sites are located at the Division of...

  • Decisions Update.  // PharmaWatch: Biotechnology;July 2005, Vol. 4 Issue 7, p11 

    The article reports that Canada-based biotech firm Lorus Therapeutics Inc. has been granted orphan drug status in the EU for its lead pancreatic cancer treatment Virulizin. The drug already holds orphan status in the U.S. Lorus believes this endorsement indicates that the product has the...

  • Lorus to advance its anticancer drug, GTI-2501 into phase II clinical trial.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p26 

    Announces the plan of Lorus Therapeutics to advance its antisense, anticancer drug, GTI-2501 into a phase II clinical trial for the treatment of advanced metastatic prostate cancer, in the fall of 2003. Mechanism of action of GTI-2501 observed during preclinical investigations.

  • R&D Update -- Other Cancers.  // PharmaWatch: Cancer;March 2003, Vol. 2 Issue 3, p11 

    Reports developments in research and development related to cancer treatment as of February 2003. Approval of the Data Safety Monitoring Board to the continuation of the thymitaq liver cancer trial of Eximias Pharmaceutical Corp.; Expansion of the renal cell carcinoma trial of Lorus Therapeutics...

  • Lorus wins patent for new leukemia drug.  // PharmaWatch: Cancer;Sep2008, Vol. 7 Issue 9, p8 

    The article reports on the patent issued by the U.S. Patent and Trademark Office to Lorus Therapeutics Inc.'s clinical-stage anticancer drug LOR-2040. It reveals that the patent protects the drug from being used in treating leukemia, along with chemotherapy drugs as well as solid cancers. The...

  • U.S. Patent Disclosures.  // BioWorld Today;2/ 7/2013, Vol. 24 Issue 26, p8 

    The article offers information related to drug patent disclosure in the U.S. including Anergis for its AllerT for birch pollen allergy, Kiadis Pharma BV for its lead product ATIR, and Lorus Therapeutics Inc. for its IL-17E for cancer treatment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics